Introduction
The parasympathetic (cholinergic) nervous system represents the main excitatory neural pathway in the airways of mammals as well as in humans (Racké and Matthiesen, 2004) . It plays a predominant role in the control of distal airway resistance although the density of parasympathetic innervation is greatest in proximal airways and diminishes peripherally (Barnes, 1986) . ACh released from cholinergic nerve terminals regulates airway functions (smooth muscle tone and mucus secretion) through stimulation of muscarinic ACh receptors (mAChRs; Alexander et al., 2008) . These receptors are members of the rhodopsin-like family of seven transmembrane receptors. Their predominant mode of signalling is mediated by the activation of GTP-binding proteins (G-proteins) , although activation of other signalling molecules also occurs (Hall et al., 1999) . Five (M 1 -M 5 ) different subtypes of mAChRs have been identified by molecular biological techniques, but so far a convincing pharmacological and functional characterisation has been provided for four of them (M 1 -M 4 ) only. Nonetheless, there is now emerging evidence that the M 5 gene forms a functional M 5 mAChR (Eglen and Nahorsky, 2000) .
The distribution of mAChRs in airways has been mapped by receptor autoradiography and in situ hybridization (Mak and Barnes, 1990; Mak et al., 1992; Hislop et al., 1998) , and binding and functional studies revealed that at least three mAChR subtypes, namely M 1 , M 2 and M 3 , are expressed in airway smooth muscle and lung parenchyma of most mammals, including humans (Gies et al., 1989; Roffel et al., 1990; Patel et al., 1995; ten Berge et al., 1996) . The presence of M 1 receptor mRNA was described in human (Bloom et al., 1988; Mak and Barnes, 1989; Mak et al. 1992) and pig peripheral lung (Haddad et al., 1994; Hislop et al., 1998) , whereas M 2 and M 3 subtypes were found in smooth muscle preparations from these (Gies et al., 1989; Roffel et al., 1993; Haddad et al., 1994; Watson et al., 1995) and other species, including rodents and ruminants (see Eglen et al., 1996 for review) . Under basal conditions, the M 3 receptor subtype is that involved in the bronchoconstriction action in all species. There is no evidence for expression of M 4 or M 5 receptors in human lung (Mak et al., 1992) , although the presence of the M 4 receptor subtype is supported by in situ hybridization (Dörje et al., 1991a; Mak et al., 1993; Yasuda et al., 1993) and binding experiments in the rabbit (Lazareno et al., 1990) and pig lung (Chelala et al., 1998) , indicating important species difference in the distribution and subtype of expressed receptors (Barnes, 2004) .
Antimuscarinic agents are currently used in treating bronchoconstriction associated with chronic obstructive pulmonary disease and certain forms of asthma (Gosens et al., 2006) , as an increase in cholinergic activity is a prominent pathophysiological mechanism in these conditions. Thus, mAChRs represent an attractive target for the development of novel antagonists that selectively block functional receptors in the effector cells; today, however, it is still a matter of controversy which animal species represents the best model for the search of bronchodilator antimuscarinic agents for human use (Barnes, 2004) .
The present study was designed to assess whether the distribution and the function of mAChRs in the airways of the pig, an excellent animal model for biomedical research, closely resemble those observed in humans. For this purpose, strips of porcine bronchi, denuded of mucosa to minimize the influence of airway epithelium (Stuart-Smith and Vanhoutte, 1988; D'Agostino et al., 1990) were used. The neuromuscular structure of the preparation was assessed by electron microscopical techniques. A characterization of mAChRs subtypes was carried out with a series of mAChRs antagonists, investigated in radioligand binding and functional experiments. The comparison of the results obtained here with published morphological and pharmacological findings revealed a similarity of porcine bronchi to human bronchi. Based on this evidence, porcine bronchi appear an appropriate animal model for studying novel mAChR antagonists targeted to a more efficacious therapeutic control of airway diseases.
Methods

Tissue preparation
Lungs of mature large white pigs (45 months, carcass weight 180-200 kg) were obtained from a local abattoir and rapidly transported to the laboratory. The bronchial tree was dissected and rings (5-6 mm I.D.) of segmental bronchi (third order) were isolated. The mucosa was removed from the tissue by rubbing the luminal surface with a moistened pipe cleaner. Histological inspection by light microscopy indicated that such procedure did not damage the basal membrane (not shown; see Klapproth et al., 1997) . The muscularis was carefully lifted away from underlying cartilage and connective tissue by using a surgical knife. Strips (4 mm width, 15-18 mm length and 40-60 mg wet weight) were obtained from transverse rings of airway wall.
Electron photomicrography
Specimens of bronchial smooth muscle were fixed for 4 h at 4 1C in 3.5% glutaraldehyde, dissolved in Millonig's phosphate buffer at pH 7, washed in Millonig's buffer, postfixed in a 1% osmium tetroxide solution in Millonig's buffer for 1 h at 4 1C and dehydrated in ascending concentrations of ethyl alcohol. Specimens were then treated with propylene oxide, embebbed in Epon 812, and cut into semithin and ultrathin sections using a Reichert OM 12 ultramicrotone. Semithin sections for light microscopy were stained with toluidine blue. Ultrathin sections were stained with uranyl acetate and lead citrate, and then examined with a Zeiss 109 electron microscope.
Binding experiments
Bronchial strips, prepared as described above, were homogenized with an Ultraturrax at full speed for 30 s, followed by homogenization in a glass-on-teflon homogenizer in Na þ / Catalli et al., 2002) . In each preparation, a cumulative concentrationresponse curve was determined twice, 60 min apart, for any mAChR receptor agonist: McN-A 343 (3-300 mM), carbachol (0.01-30 mM), bethanecol (0.1-300 mM), methacholine (0.01-100 mM), muscarine (0.01-30 mM), oxotremorine (0.01-30 mM) and muscarone (0.01-1 mM).
The antagonist properties of the mAChR blockers were evaluated on concentration-response curves produced by muscarone. After construction of the first muscarone concentration-response curve, a 30 min washout period was allowed to return the basal tone (that is, 10 mN). The preparation was then exposed for 30 min to one of the following antagonists: atropine (1-30 nM), pirenzepine (1-10 mM), AF-DX 250 (3-30 mM) , methoctramine (1-10 mM), tripitramine (1-10 mM), HHSiD (0.03-1 mM), 4-DAMP (10-100 nM), DAU 5884 (10-100 nM), pF-HHSiD (0.1-10 mM) and AQ-RA 741 (0.3-3 mM). A second muscarone concentration-response curve was then carried out in the presence of the antagonist under test. Only one concentration of antagonist was tested on each preparation and at least three increasing concentrations were assayed in separate experiments. The pA 2 values were determined according to Arunlakshana and Schild (1959) . Time-matched control experiments were carried out in the absence of antagonists.
Calculation and statistical analysis
The maximal binding site (B max 
; Cheng and Prusoff, 1973) and converted to pK i (ÀlogK i ).
In functional experiments, agonists' potency values were expressed as ÀlogEC 50 , where EC 50 indicates molar agonist concentration inducing 50% of the maximum effect of the curve evaluated by nonlinear curve fitting. Intrinsic activity (a) of an agonist was determined as percentage of muscarone maximal response. Antagonists affinity (pA 2 ) values were determined by the Schild regression analysis, using agonist concentration ratios determined at EC 50 levels on concentration-response curves in absence and in presence of antagonist (Arunlakshana and Schild, 1959 ). Means ± s.e.m. and confidence limits at 95% probability were evaluated by using a computer program (PHARM/PCS, version 5). Carbachol, bethanecol, methacholine, oxotremorine, carbamoyl]oxy]-2-butynyltrimethylammonium chloride (McN-A343), atropine, pirenzepine and indomethacin were purchased from Sigma Chemical Company (St Louis, MO, USA); 4-diphenylacetoxy-N-methyl-piperidine (4-DAMP), 11-[[4-[4-(diethylamino) butyl]-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyrido (2,3-b) (1,4)benzodiazepine-6-one (AQ-RA 741), muscarine, para-fluorohexahydrosiladifenidol (pF-HHSiD), HHSiD and methoctramine were purchased from Research Biochemicals, Natick, MA, USA); mamba toxin-3 (MT3) from Peptide International (San Diego CA, USA).
Drugs and chemicals
Quinuclidinyl benzilate (QNB) was synthesized at Dr Karl Thomae GmbH (Biberach, Germany); 8-methyl-8-azabicyclo-3-endooct-3-yl-1,4-dihydro-2-oxo-3(2H)-quinazoline carboxylic acid ester (DAU 5884) and dextrorotatory 11-(À1-piperdinyl] acetyl)-5,11-dihydro-6H-pyridobenzodiazepine-6-one (AF-DX 250) were provided by Boehringer Ingelheim Italy (Milan, Italy) .
[N-methyl- 
Results
Electron microscopy study The ultrastructural morphology of the bronchial smooth muscle strips, devoid of epithelium, was investigated by transmission electronic microscopy. The smooth muscle cells were arranged in bundles and separated by space containing an amorphous matrix. No ganglia were evident. Nerve fasciculi related to smooth muscle ran parallel to muscle bundles ( Figure 1a ) and close contacts with smooth muscle membrane were more reliably detected when muscle bundles were cut in cross-section ( Figure 1b ). Micrographic analysis also revealed that in porcine bronchi most nerve fibres presented axonal varicosities containing predominantly (along with few large granular vesicles) or exclusively small agranular vesicles. Their profile resembles the profile of cholinergic nerves in primates and humans (El-Bermani and Grant, 1975; Daniel et al., 1986) .
Binding experiments
In crude membrane homogenates prepared from porcine bronchi in Na According to Scatchard and Hill plot analyses, the pirenzepine displacement-curve fitted a single-site model (n H ¼ 0.89 ± 0.04; pKi ¼ 6.43). At variance, nonlinear least squares regression analysis of occupancy-concentration curves of DAU 5884, methoctramine and tripitramine differed from a one-binding-site model. Hill coefficients significantly less than unit (n H ¼ 0.75 ± 0.03, 0.73 ± 0.06 and 0.78±0.05, respectively) could reflect the presence of a heterogeneous population of mAChRs.
DAU 5884 showed a best fit to a two-site model, with high affinity (pK i ¼ 8.29) and low affinity (pK i ¼ 7.05) for 23% and 77% of receptor sites, respectively. According to the twobinding-site model, methoctramine recognized with high affinity (pK i ¼ 7.87) 86% of binding sites and displayed low affinity (pK i ¼ 7.06) for the remaining 14%. A similar pattern was observed for tripitramine, the recognized proportion being equivalent to 78% (pK i ¼ 8.91) and 22% (pK i ¼ 7.10) of total bindings sites. As regards MT3, the peptide from green mamba venom, this peptide was completely inactive in the range of concentrations used (10-1000 nM).
The binding parameters of the mAChR antagonists used here are summarized in Table 1 .
Functional experiments
A series of mAChR agonists induced concentration-dependent contraction of the smooth muscle bronchial strips. All the compounds behaved as full agonists, compared to muscarone, except oxotremorine and McN-A 343, which showed a maximal contractile response (E max ) of 80.04 ± 1.1 and 21.8±6%, respectively. The rank order of potencies (ÀlogEC 50 ) was muscarone (6.9 ± 0.06; n ¼ 6)4oxotre-morine (6.82 ± 0.09; n ¼ 4)4carbachol (6.38 ± 0.09; n ¼ 5)4 Abbreviations: DAU 5884, 8-methyl-8-azabicyclo-3-endooct-3-yl-1,4-dihydro-2-oxo-3(2 H)-quinazoline carboxylic acid ester; MT3, mamba toxin-3; NMS, [N-methyl-3 H]scopolamine methyl chloride; ND, not determined. IC 50 and expression values are the geometric means and 95% confidence limits (in brackets) of n (4-6) displacement experiments run in triplicate; n H , Hill coefficient (n H ± s.e.m.). *n H significantly less than unity (Po0.05).
muscarine (6.33 ± 0.10; n ¼ 6)4methacholine (6.07 ± 0.08;
The first and the second concentration-response curves of muscarone were superimposable. The muscarone concentration-response curve was shifted to the right in a parallel manner and without depression of the maximal response by atropine or subtype-preferring mAChR blockers, thus, indicating competitive antagonism as shown by Schild plot analysis ( Figure 2 ). Postjunctional pA 2 values are listed in Table 2 and compared with affinity estimates for the same antagonists at human M 1 -M 5 subtypes stably expressed in CHO (Chinese hamster ovary) cells. Their correlation analysis is shown in Figure 3 . In Table 3 , the postjunctional pA 2 values in pig bronchi are compared with corresponding pA 2 /pK B values obtained in human bronchi.
Discussion and conclusions
Acetylcholine exerts its effects on smooth muscle, nerves and secretory cells through activation of mAChRs (Barnes, 1987) . These receptors were described on different target cells by means of different techniques, but the narrow 'selectivity window' of mAChR ligands used in the past generated some uncertainty about the expression of the mAChRs subtypes involved in the control of airway functions (see Racké and Matthiesen, 2004, for review) . In this study, we used isolated bronchi of the pig, an excellent animal model for biomedical research, as a large body of evidence supports the notion that pigs and humans are similar in many aspects of both infant and adult anatomy, physiology, biochemistry, pathology and pharmacology (Hawarth and Hislop, 1981; Eglen et al., 1996) . Table 2 . mAChR, muscarinic acetylcholine receptor. (2,3-b) (1,4)benzodiazepine-6-one; CHO, Chinese hamster ovary; 4-DAMP, 4-diphenylacetoxy-N-methyl-piperidine; DAU 5884, 8-methyl-8-azabicyclo-3-endooct-3-yl-1,4-dihydro-2-oxo-3(2 H)-quinazoline carboxylic acid ester; HHSiD, hexahydrosiladifenidol; pF-HHSiD, parafluorohexahydrosiladifenidol; mAChR, muscarinic acetylcholine receptor; MT3, mamba toxin-3; ND, not determined. Data from: (a) Dörje et al. (1991b) ; (b) Maggio et al. (1994) ; (c) Eglen and Nahorski (2000); (d) Buckley et al. (1989) ; (e) Chelala et al. (1998) ; (f) Guo et al. (1995) ; (g) unpublished data; (h) Hedge et al. (1997) .
In this respect, transmission electronic microscopy photomicrographs of sections of pig bronchial strips, offering a fine anatomical view of the neuromuscular structure, support the similarity of porcine with human bronchi (Daniel et al., 1986; van Koppen et al., 1988) . The morphological analysis showed a preponderance of small agranular vesicles which are characteristic of cholinesterase-positive cholinergic nerve terminals, innervating the bronchial smooth muscle of large mammals and primates (El-Bermani and Grant, 1975; van Koppen et al., 1987) . Based on this evidence, our strategy was to obtain an appropriate characterization of mAChRs in this bronchial preparation by means of a series of subtypepreferring mAChR antagonists. (Haddad et al., 1994) and human airways (van Koppen et al., 1985 (van Koppen et al., , 1988 . With regard to the characterization of the mAChRs, the [ 3 H]NMS displacement curve for the M 1 antagonist pirenzepine was best fitted to a one-bindingsite model with a pK i of 6.43, a value close to that found for human cloned M 2 receptors (6.65; see Table 2 , for comparison), thus excluding the participation of the M 1 receptor subtype. Conversely, a Hill coefficient significantly less than unity for DAU 5884 (M 1 /M 3 selective), methoctramine (M 2 /M 4 selective) and tripitramine (M 2 selective), suggests the presence of a heterogeneous expression of mAChRs in Figure 3 Correlation of postjunctional affinity (pA 2 ) values at mAChRs in pig bronchi with corresponding affinity constants (pK i ) at human cloned muscarinic receptor subtypes (hM 1 -hM 5 ) expressed in CHO cells. r ¼ correlation coefficient of Pearson; SSQ ¼ sum of squares of differences between affinity estimates (S(x-y) 2 ). CHO, Chinese hamster ovary; mAChRs, muscarinic acetylcholine receptors.
porcine bronchi (Table 1 ). The high affinity values of methoctramine and tripitramine and the low affinity value of DAU 5884 are in agreement with the pharmacological profile of an M 2 receptor subtype, whereas the low affinity values of methoctramine and tripitramine and the high affinity value of DAU 5884 are consistent with the presence of a minor population of M 3 /M 5 receptors (Table 2) . Based on these data, the dominant receptor subtype representing approximately 80% of receptor sites (Table 1) , is an M 2 mAChR, a finding also corroborated by the high level of M 2 mRNA transcript (Haddad et al., 1994) .
The presence of a putative M 4 mAChR subtype was excluded by the apparent inefficacy of MT3, used at concentrations that produce a complete blockade of the M 4 mAChR subtype. The MT3 peptide used in this study is known to be effective against the M 4 mAChR subtype as it showed activity in the human isolated detrusor (data not shown), a preparation which expresses these receptors (D'Agostino et al., 2000) . In this respect, the absence of M 4 mRNA in porcine bronchi (Haddad et al., 1994) should be noted.
The identification of the minor M 3 /M 5 receptor population was achieved with the use of previous (pirenzepine, methoctramine, tripitramine and DAU 5844) and additional mAChR antagonists (atropine, AF-DX 250, AQ-RA 741, 4-DAMP, HHSiD and pF-HHSiD) in functional contractile smooth muscle experiments. Porcine bronchi contracted following exposure to the mAChR agonists muscarone, carbachol, muscarine, methacholine and bethanecol, demonstrating full agonist properties, whereas oxotremorine and Mc-NA 343 behaved as partial agonists. The concentration-response curve induced by the most potent agonist, muscarone, was shifted in a competitive fashion by all the mAChR blockers with a slope not significantly different from unity, probably indicating the involvement of a single muscular mAChR subtype. The high affinity values obtained for atropine, 4-DAMP and DAU 5884, the intermediate affinity values for HHSiD, pF-HHSiD, pirenzepine and tripitramine, as well as the low affinity estimates for methoctramine and AF-DX 250 (see Table 2 ) suggest a prevalent M 3 mAChR pharmacological profile. Nevertheless, the participation of the M 5 receptor subtype could not be excluded a priori, given the similarity in M 3 and M 5 profiles (difference oten-times) of the antagonists used. The use of AQ-RA741, a ligand with preferential affinity (difference 410-fold) for the M 3 over the M 5 receptor in animal and human tissues (Eglen and Nahorsky, 2000) , strongly suggested that M 3 mAChRs mediate contractions of porcine bronchial smooth muscle. This conclusion is also supported by the finding of an excellent correlation between pA 2 values obtained in pig bronchi and those obtained in CHO cells expressing the human M 3 receptor (Figure 3c ). The data generated in pig bronchi are also largely consistent with those obtained in human tracheal and bronchial preparations (Roffel et al., 1990; Watson et al., 1995) suggesting that the same mAChR subtype (that is, the M 3 subtype) is coupled to contraction. The difference in affinities observed with methoctramine, HHSiD and pF-HHSiD in human and pig bronchi could be explained in several ways. In human bronchi, methoctramine (3-300 mM) causes irregular rightward shifts of agonist concentration-effects curves accompanied by depression of the curve maximums, thereby, compromising estimation of its affinity. As far as HHSiD and pF-HHSiD are concerned, both compounds show some variability in pA 2 values for the M 3 receptor subtype, which are tissue and species-dependent. As such, the utility of these antagonists in muscarinic receptor classification is limited (Eglen et al., 1990) .
In conclusion, isolated porcine bronchi seem to be a reliable model system to study mAChR function in peripheral airways and may represent an useful tool in the screening and development of novel bronchodilator agents for the therapy of airway diseases in humans. 
t r a c t
Various forms of low urinary tract symptoms (LUTS) seem dependant upon dysregulation of the purinergic pathway which produces sensory-or motor-activated incontinence. A body of evidence in human urinary bladders supports a link between up-regulation of purinergic activity and the pathogenesis of detrusor instability. This study investigated the potential role of adenosine 5 -triphosphate (ATP) in the control of detrusor motor drive in a model of porcine urinary bladder. The involvement of ATP on excitatory activity was assessed by measuring neurally-evoked [ 3 H]-acetylcholine (ACh) release and smooth muscle contraction in detrusor strips. Epithelium-deprived preparations were used to minimize the influence of non-neural sources of ACh and ATP on parasympathetic neurotransmission. ACh release and smooth muscle contractility were not significantly affected by neural ATP in normal detrusor, but markedly enhanced when ATP hydrolysis was reduced by ectoATPase inhibitors, as well as by ␣,␤-methylene-ATP (ABMA), agonist resistant to ecto-enzymes degradation. Prejunctional P2X receptors located on cholinergic nerves are involved in such potentiating effect. These purinergic heteroreceptors were characterized as P2X 3 subunits by means of the putative antagonists: NF449 (P2X 1,3 selective), NF023 (P2X 1,3 selective), PPNDS (P2X 1 selective) and A-317491 (P2X 3 selective). In porcine detrusor, P2X 3 receptors are functionally expressed at neural site facilitating neurogenic ACh release. When purine breakdown is experimentally down-regulated to mimicking the impaired purinergic pathway observed in pathological human bladders, endogenous ATP can markedly enhance detrusor contractility through activation of these receptors. Since P2X 3 blockade represents a potential therapeutic approach for diseases of the urinary tract, isolated porcine detrusor represents a reliable model for development of novel selective P2X 3 antagonists beneficial in the treatment of detrusor hyperactivity.
© 2011 Elsevier Ltd. All rights reserved. 
Introduction
Adenosine 5 -triphosphate (ATP), a co-transmitter in most nerves in the peripheral nervous system, represents a prime candidate between modulators determining up-and down-regulation of synaptic transmission [1] . Although in such mechanism the breakdown product adenosine seems partly involved, a substantial body of evidence supports the notion that ATP can act directly through specific receptor types, ranging from P2Y to P2X receptor families [2] . This last family includes seven (P2X 1-7 ) receptor subunits which can form either homomultimeric or heteromultimeric structures related to nonselective calcium channel opening [3] . Different P2X subunits were identified in a wide variety of tissues in peripheral organs [4] , including the urinary bladder where P2X 1,2,4 subunits are present on detrusor muscle-cells, P2X [1] [2] [3] 5 on bladder nerves and P2X 2, 3, 7 subunits are located on urothelial cells [5] . In this organ, ATP is co-stored and released together with 1043-6618/$ -see front matter © 2011 Elsevier Ltd. All rights reserved. doi:10.1016/j.phrs.2011.10.002 the main neurotransmitter acetylcholine (ACh) [6] , contributing to nerve-mediated bladder contraction and urine elimination [7, 8] . The relative importance of the purinergic component, however, is species dependent, being dominant in cat, mouse and rabbit, to moderate in guinea pig, rat and dog, to less pronounced in pig and humans [9] . Although negligible in normal human bladder [10] , the role of ATP has recently attracted considerable attention in the pathophysiology of abnormal detrusors [11] . In fact, the purinergic component seems responsible for the increased atropine-resistance of parasympathetically-evoked contractions observed in aging [12] and in subjects with urological disease states such as obstructed bladder (OB) [10, 13] and interstitial cystitis (IC) [14] , or idiopathic detrusor overactivity (IDO) [15] , where the magnitude is greatest [16] . For those patients suffering from a high prevalence of detrusor instability, current treatment options include muscarinic antagonists, drugs with challenging tolerability profile and marginal efficacy [17] . This suboptimal management leaves a relevant opportunity for the development of superior therapeutics surfaced through the discovery of novel receptor targets.
In this respect, prejunctional heteroceptors that serve a combined function in sensory and motor pathway of the human bladder have been suggested as potential pharmacological targets [18] [19] [20] . Recently, neural P2X 3 receptors have been suggested to exert a prominent role in the control of bladder fullness sensation and efferent transmitter release in pathophysiological circumstances [21] , in particular in human bladders with detrusor overactivity (DO) where an increase in P2X 3 receptor expression was observed too [22] .
Consequently, the blockade of these receptors might be clinically beneficial [21, 23, 24] , but the development of novel P2X 3 antagonists requires a first screening of their pharmacological activity in an animal model in which compelling evidence has surfaced that a dysregulation of the purinergic pathway promoting conditions of functional neurologic hyperactivity relates to motor (efferent) urologic abnormalities.
For this purpose we used the urinary bladder of the pig, considered a reliable animal model for urological research from many aspects [25] [26] [27] [28] [29] but, in particular, from the notion that the quantity of released ATP, proportion of ATP release from neuronal (parasympathetic terminals) and non-neural sources (urothelium) as well as ecto-ATPase activity affecting purine levels are remarkably similar between pig and humans [8] .
The aim of the present study was to provide direct evidence that neurogenic ATP and P2X receptors are involved in the control of detrusor motor drive, determining detrusor smooth muscle hyperactivity in conditions of up-regulation of purinergic pathway. Accordingly, [ 3 H]-ACh release and contractile experiments were carried out in the isolated detrusor of the pig, epithelium-deprived to minimize the influence of non-neural sources of ACh and ATP in the characterization of neural P2X receptors.
Materials and methods
Materials
The following compounds were purchased: [methyl-3 H]-choline chloride (2.89 TBq/mmol) from Amersham (Arlington Heights, IL, USA); TTX, -conotoxin GVIA, Suramin, 4, 4 , 4 , 1, )] tetrakis-1,3 benzenedisulfonic acid, octasodium salt (NF449), and 4-(2-[7-amino-2-(2-furyl) [1, 2, 4] triazolo [2,3-a] 5-[[[(3-phenoxyphenyl) 8,8 -[carbonylbis(imino-3,1-phenylenecarbonylimino) ]bis-1,3,5-naphthalene-trisulfonicacid, hexasodium salt (NF023), pyridoxal-5 -phosphate-6-(2 -naphthyl azo-6 -nitro-4 ,8 -disulfonate) tetrasodium salt (PPNDS), 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) and potato's apyrase grade III from Sigma-RBI (St. Louis, MO, USA).
Preparation of porcine detrusor strips
Specimens from the anterior part of the urinary bladder dome of Dumeco strain male pigs (>5 months, carcass weight 180-200 kg), obtained from local abattoir, were transported to the laboratory in gassed (95% O 2 and 5% CO 2 ) Krebs' solution containing (mM): NaCl 120, KCl 4.7, MgSO 4 0.6, NaHCO 3 25, KH 2 PO 4 1.2, CaCl 2 2.0 and glucose 10 at 6 • C. Muscle strips (20 mm long, 4 mm wide), prepared by removing serosal and mucosal layers, were mounted isometrically under an initial tension of 2 g in 2 ml perfusion chamber superfused with Krebs' solution at 37 • C. Electrical field stimulation (EFS) was applied by means of two platinum electrodes placed parallel to the preparation.
The study was approved by the Animal Ethics Committee of University of Pavia and complies with the current Italian laws.
Release experiments in porcine detrusor strips
After a 30 min equilibration period, neuronal release of [ 3 H]-ACh was assessed according to the procedure previously described for the human bladder [20] . Briefly, the preparation was incubated for 45 min with [methyl-3 H] choline (92 kBq/ml) and stimulated by 10 s pulse trains delivered at 10 Hz (0.2 ms duration, 60 V/cm, 60 s apart) to label neuronal ACh stores. Following loading, the preparations were washed out for 120 min by superfusion at a constant rate of 2 ml/min (Minipulse 2HP8 flow inducer, Gilson Medical Electronics, Middleton, WI, USA). Hemicholinium-3 (10 M) was present in the superfusion solution throughout the experiment to prevent choline uptake. Starting at the 121st min (zero time), the fluid was collected continuously in 3 min periods (6 ml samples) and aliquots (1 ml) were measured in 3 ml of Ultima Gold (Packard BioScience, Groningen, The Netherlands) scintillation cocktail by liquid scintillation spectrometry (Tri-Carb 2700TR, PerkinElmer, Shelton, CT, USA). Quench correction curves were established and external standardization was used for counting efficiency (% counting efficiency: 59 ± 1.8). Tritium content was expressed in disintegration per s (Becquerel) for gram of dry weight of the tissue (Bq/g) determined at the end of the experiment.
The strips were stimulated 2 times by EFS (S 1 and S 2 ) beginning 9 (S 1 ) and 54 (S 2 ) min after zero time with 6 trains of 9 s, delivered at 20 Hz (0.1 ms durations, 90 V/cm) 33 s apart. The EFS (S 1 and S 2 ) caused an increase of [ 3 H]-outflow that was calculated as difference between the total tritium outflow during 3 min stimulation plus the following 12 min (stimulation outflow period) and the calculated spontaneous outflow. The decline for the spontaneous outflow was calculated by fitting a linear regression line to the values (expressed in Bq/g) of 3 min-samples before and after the stimulation outflow period.
The exposure of P2X agonists was allowed either 2 min before the onset of S 2 (preliminary set of experiments) or during the second train of S 2 (along the study). Other drugs were added to the superfusional fluid 10 min (P2X antagonists, ecto-ATPase and ecto-ATPase inhibitors) and 20 min (TTX, -conotoxin GVIA, hexamethonium, atropine) before the onset of S 2 . The change in the ratio between the [ 3 H]-outflow evoked during the two stimulation periods (S 1 /S 2 ) compared to that observed in control situations (S 1 /S 2 in the absence of tested drugs) was taken as a measure of the effect of tested drugs.
Accordingly, concentration-response curves (CRCs) for ATP and ␣,␤-meATP (ABMA) were constructed in the absence and in the presence of P2X antagonists.
Contractile assessments in porcine detrusor strips
In the same experiment, the EFS effectiveness in producing ACh release was also assessed by measuring muscular contractile effects on a polygraph (Battaglia Rangoni, Bologna, Italy). Smooth muscle contractions (C 1 and C 2 ) were assessed as the sum of the six contractions evoked by S 1 and S 2 , respectively. The change in the ratio C 2 /C 1 was taken as a measure of the effect of tested drugs.
Statistical analysis
Values from individual experiments were averaged, and the SEM values were calculated. Drug potency estimates were evaluated as −log EC 50 (negative log of the molar concentration-producing halfmaximal effect) by nonlinear curve fitting (GraphPad Prism, version 5; GraphPad Software Inc., San Diego, CA). Apparent affinity (pK i ) estimates were calculated according to Kenakin [30] . Differences between means were analyzed with one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison test. Values of p < 0.01 were taken as statistically significant.
Results
Neural and muscular effects evoked by EFS
The experimental approach used in this study allowed to record simultaneously in each experiment both prejunctional (neural In pig isolated detrusor strips, EFS produced a contractile response (C 1 ; 7.66 ± 2.09 g, n = 20) and a marked 3 H-outflow (S 1 ; 7591 ± 860 Bq/g dry tissue) ( Fig. 1A and B) . In control experiments, the second EFS induced similar contractile and outflow patterns, showing a C 2 /C 1 and S 2 /S 1 ratio value of 0.93 ± 0.03 and 0.82 ± 0.02, respectively.
In the presence of 5 M TTX, EFS-evoked contractile response and [ 3 H]-outflow were reduced of 92 ± 3% and 84 ± 8%, respectively (n = 3; Figs. 1C, D and 2), but not affected by the ganglionic blocker hexamethonium (10 M) (n = 3; Fig. 1E and F) .
At variance, atropine mostly abolished the EFS-evoked contractile effect (by about 91% at 1 M; not shown). The N-type Ca 2+ -channel blocker -conotoxin GVIA (0.1-3 M) reduced concentration-dependently the [ 3 H]-outflow (83 ± 5% maximal inhibition; Fig. 2 ). Taken together, these data indicate that the 3 H-outflow mostly reflects the release of neural [ 3 H]-ACh from cholinergic terminals, as previously observed in human detrusor [20] .
Purinergic ligands affected the EFS-evoked effects to different extents, depending on the used experimental conditions. When exposed 2 min before S 2 , the purinergic agonists ATP and ABMA (1 M to 1 mM) failed to affect both contraction and [ 3 H]-ACh release evoked by EFS, but increased the smooth muscle basal tension of the strip without any significant change of basal spontaneous [ 3 H]-outflow. The musculature was concentrationdependently contracted, but in a reproducible manner only for ABMA with a maximal extent at 300 M (45 ± 8% of EFS-evoked contraction; n = 6; Fig. 3B ). The partial agonist Bz-ATP (1 M to 1 mM) revealed to be ineffective.
Conversely, when added during S 2 , ATP produced a facilitation of EFS-evoked [ 3 H]-ACh release that was measurable (8.3 ± 2% maximal enhancement, n = 3; Fig. 4 ) but not significant (p = 0.048), likely due to a fast-desensitization [5] and competition [31] induced by endogenous ATP on P2X receptors.
To minimizing these effects, a 10 min pretreatment with apyrase, an ATP/ADPase that dephosphorylates ATP to ADP than to AMP, was used. In the presence of 4 U/ml apyrase, exogenously applied ATP during S 2 , but not the P2X 1,7 selective agonist Bz-ATP (p = 0.05; n = 5; ARL67156. In the presence of this drug at a concentration which likely prevents, albeit not totally, ATP conversion without affecting adenosine levels [32] , the neurogenic contraction was enhanced too (by 72 ± 7, n = 4; p = 0.004; Fig. 5 ).
These results suggest that the observed inability of endogenous ATP to induce a significant facilitatory effect on cholinergic activity in normal detrusor strips is likely the result of the break down rate of ATP occurring in the parasympathetic cleft.
To characterize the type(s) of purinergic receptors affecting EFS-evoked [ 3 H]-ACh release and contraction, the CRC of ATP was carried out in the presence of adenosine receptors antagonists. The blockade of inhibitory A 1 and excitatory A 2A adenosine receptors with 100 M DPCPX and ZM 241385, respectively selective antagonists for A 1 and A 2A receptor subtypes, did not produce any significant variation on both [ 3 H]-ACh release and contraction (data not shown). Conversely, the behaviour of CRCs of ABMA was affected in the presence of P2X receptors antagonists, whose selectivity is listed in Table 1 [31, [33] [34] [35] .
The CRC of ABMA was antagonized by 1 M suramin (Fig. 6A ), but was not affected by 10 M NF023 (Fig. 6B) nor by 100 nM PPNDS or by NF449 at nanomolar concentrations (not shown). At variance, the CRC of ABMA was competitively antagonized by NF449 at micromolar concentrations (Fig. 6C) and by 100 nM A-317491, putative potent antagonist for P2X 3 monomer (Fig. 6D) .
From CRCs the pharmacodynamic parameters of the used ligands were calculated and listed in Table 1 together with their published pEC 50 /pIC 50 values at P2X subunits. The comparison of the obtained pIC 50 /pK i of any selective antagonists with their affinity values at P2X subunits is consistent with the notion that P2X heteroceptors located at cholinergic side belong to P2X 3 receptors.
The EFS-evoked contractile effect in normal detrusor strips was cholinergic in origin since it was mostly abolished by atropine in control experiments (by about 91% at 1 M; not shown). At variance, an atropine-resistant component was present in the enhanced EFS-evoked contractions induced by ABMA. In fact, these neurogenic contractions were sensitive but not suppressed by 1 M atropine, which produced only a right shift of CRC of ABMA, without abolishing it (Fig. 7B) .
In an attempt to characterize such non-cholinergic component, the neurogenic contractions enhanced in the presence ABMA were studied in a separate set of experiments after the complete blockade of P2X 1 receptors with 100 nM NF449 (pK i 9.5 at P2X 1 receptors). In this case too, the CRC of ABMA was shifted to the right but not flattened by NF449.
Discussion
It is widely accepted that parasympathetic postganglionic nerves supplying mammals urinary bladder use ACh and ATP as co-transmitters, in proportions variable in different pathophysiological circumstances [6] . Our findings, corroborating the notion that parasympathetically-released ACh and ATP represent excitatory neurotransmitters to smooth muscle of porcine detrusor [8, 36, 37] , demonstrate that the functional motor drive in physiological conditions prevalently depends on ACh. One account of the negligible participation of neurogenic ATP in eliciting smooth muscle contraction could be due to the accelerated breakdown of the purine that occurs in the synaptic cleft of normally active porcine bladder. Our data likely support the above suggestion, since the purinergic component reemerges to play a significant role in the efferent signalling pathway when the enzymatic hydrolysis of ATP was experimentally reduced. As of the matter of fact, in the presence of the potent ecto-ATPase inhibitor ARL67156, endogenous ATP released in response to nerve stimulation can significantly enhance [ 3 H]-ACh release and, in turn, smooth muscle contraction. In consideration of the use of ARL67156 at a fixed concentration, which prevents but not able to produce total inhibition of the ectoATPase activity [32] , agents resistant to ecto-ATPases degradation would be expected to induce a more effective enhancement. Really, a marked potentiation (by about 250%) was produced in normal detrusor strips by the non-hydrolyzable ATP analog, ABMA.
Based on the notion that ABMA is a potent agonist to P2X 1 and P2X 3 receptors [3] , the purinergic excitatory motor drive seems to be essentially dependent on the activation of these P2X subtypes. On the other hand, the involvement of the breakdown product adenosine has to be excluded, as the blockade of specific inhibitory A 1 and excitatory A 2A receptors with selective antagonists (namely, DPCPX and ZM 241385, respectively) did not produce any significant variation on [ 3 H]-ACh release.
The inefficiency of Bz-ATP (P2X 1 partial agonist) likely bars the participation of P2X 1 subunit, but a definitive characterization of the involved receptors was carried out by means of selective P2X 3 receptor antagonists. The comparison of their pharmacodynamic parameters obtained in this study with those published at P2X 1-3 human recombinant homomeric receptors (see Table 1 ) clearly suggests that the purine receptors affecting ACh release belong to P2X 3 subunit.
In conditions of up-regulation of the purinergic pathway (i.e. experimentally-reduced rate of ATP hydrolysis or stimulation with a non-hydrolyzable ATP analog), this P2X 3 -dependent prejunctional excitatory mechanism raises to a relevant role in producing smooth muscle hyperactivity. Such smooth muscle potentiation is likely due to the concomitant activation of muscarinic M 3 [28] and P2X 1 muscular receptors [5] . Indeed, the enhancement of EFSinduced contraction was atropine-resistant to a great extent (more than 50%) as well as only partially blocked by the P2X 1 antagonist NF449.
In this respect, it is noteworthy that atropine-resistance phenomenon is described in isolated strips of bladders from patients suffering for DO [5] where purinergic activity is enhanced due to a reduced degree of purine breakdown [3, 38] . Taken together, our data suggest that in a suitable animal model for urological research the purinergic-receptor mechanisms involved in potentiating detrusor motor drive comprise excitatory muscular P2X 1 as well as neural P2X 3 subunits facilitating the release of ACh, and their blockade can efficaciously contribute in reducing detrusor myocytes overexcitation in experimentally-matched pathological conditions.
Conclusion
The presence of P2X 3 subunits have been previously revealed by immunohistochemistry on the urinary bladder of mammals, prevailingly on sensory nerves and in nerve bundles beneath the urothelium [5] . Our data support the notion that P2X 3 receptors exert the role of excitatory heteroceptors on parasympathetic terminals and provide direct evidence that in pig detrusor the down-regulation of purine breakdown produces smooth muscle hyperactivity, a condition resembling that observed in human instable detrusors.
Since the up-regulation of P2X 3 receptors, predominant subunit in human bladder nerve profiles [5] , seems to be involved in generating symptoms of bladder dysfunctions [39] , orally bioavailable antagonists with selectivity for P2X 3 receptors have been suggested as potential clinical candidates in the treatment of pain-related disorders of the lower urinary tract [40] . If our findings could be extrapolated to humans, the blockade of P2X 3 heteroceptors on cholinergic terminals might represent an additional purinergic target in the control of pathological conditions of the detrusor, particularly when associated with motor (efferent) abnormalities. Therefore, since obtaining a large supply of human bladder specimens for functional assessments is not so feasible, isolated porcine detrusor provides a reliable animal model to develop novel selective P2X 3 antagonists for human use.
